User login
Key clinical point: No difference in overall survival occurred between HCC patients treated with Lipiodol
Major finding: The average overall tumor reduction was 21.45%; 19.95% in the Lipiodol-only group and 22.95% in the combination group (P = 0.653). However, patients in the combination group showed significant improvement in various degrees of tumor response compared to the Lipiodol-only group (P = 0.010).
Study details: The data come from a prospective, randomized trial of 44 men and 17 women, aged 44-85 years, with hepatocellular carcinoma who underwent transarterial chemoembolization (cTACE) using Lipiodol only or with additional use of degradable starch microspheres (DSM).
Disclosures: The study was supported by PharmaCept GmbH, Berlin, Germany. The researchers had no financial conflicts to disclose.
Source: Vogl TJ et al. Hepatol Int. 2021 May 27. doi: 10.1007/s12072-021-10193-8.
Key clinical point: No difference in overall survival occurred between HCC patients treated with Lipiodol
Major finding: The average overall tumor reduction was 21.45%; 19.95% in the Lipiodol-only group and 22.95% in the combination group (P = 0.653). However, patients in the combination group showed significant improvement in various degrees of tumor response compared to the Lipiodol-only group (P = 0.010).
Study details: The data come from a prospective, randomized trial of 44 men and 17 women, aged 44-85 years, with hepatocellular carcinoma who underwent transarterial chemoembolization (cTACE) using Lipiodol only or with additional use of degradable starch microspheres (DSM).
Disclosures: The study was supported by PharmaCept GmbH, Berlin, Germany. The researchers had no financial conflicts to disclose.
Source: Vogl TJ et al. Hepatol Int. 2021 May 27. doi: 10.1007/s12072-021-10193-8.
Key clinical point: No difference in overall survival occurred between HCC patients treated with Lipiodol
Major finding: The average overall tumor reduction was 21.45%; 19.95% in the Lipiodol-only group and 22.95% in the combination group (P = 0.653). However, patients in the combination group showed significant improvement in various degrees of tumor response compared to the Lipiodol-only group (P = 0.010).
Study details: The data come from a prospective, randomized trial of 44 men and 17 women, aged 44-85 years, with hepatocellular carcinoma who underwent transarterial chemoembolization (cTACE) using Lipiodol only or with additional use of degradable starch microspheres (DSM).
Disclosures: The study was supported by PharmaCept GmbH, Berlin, Germany. The researchers had no financial conflicts to disclose.
Source: Vogl TJ et al. Hepatol Int. 2021 May 27. doi: 10.1007/s12072-021-10193-8.